Browse by author
Lookup NU author(s): Professor Volker StraubORCiD, Emerita Professor Katherine Bushby
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Fourteen years ago, the first disease-causing mutation in a form of autosomal recessive limb-girdle muscular dystrophy was reported. Since then the number of genes has been extended to at least 14 and the phenotypic spectrum has been broadened. The generation of mouse models helped to improve our understanding of the pathogenesis of the disease and also served to study therapeutic possibilities. All autosomal recessive limb-girdle muscular dystrophies are rare diseases, which is one reason why there have been so very few controlled clinical trials. Other reasons are insufficient natural history data and the lack of standardized assessment criteria and validated outcome measures. Currently, therapeutic possibilities are mainly restricted to symptomatic treatment and the treatment of disease complications. On the other hand, new efforts in translational research and the development of molecular therapeutic approaches suggest that more promising clinical trials will be carried out in autosomal recessive limb-girdle muscular dystrophy in the next several years. © 2008 The American Society for Experimental NeuroTherapeutics, Inc.
Author(s): Straub VW, Bushby KMD
Publication type: Article
Publication status: Published
Journal: Neurotherapeutics
Year: 2008
Volume: 5
Issue: 4
Pages: 619-626
Print publication date: 01/10/2008
ISSN (print): 1933-7213
ISSN (electronic): 1545-5351
Publisher: Elsevier
URL: http://dx.doi.org/10.1016/j.nurt.2008.08.003
DOI: 10.1016/j.nurt.2008.08.003
Altmetrics provided by Altmetric
